Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Everest Medicines Ltd. ( (HK:1952) ) is now available.
Everest Medicines Limited has disclosed that non-executive director and honorary chairman Wei Fu, also a substantial shareholder, increased his stake in the company. Acting through a controlled entity, Fu bought 860,000 shares on the open market on 27 March 2026 for about HK$32.7 million, at an average price of HK$38.12 per share.
The purchase signals Fu’s strong confidence in Everest Medicines’ future prospects and long-term development, and he may further raise his holdings subject to regulatory compliance. The move is likely to be interpreted by the market as a vote of confidence from insider leadership, though the company has cautioned shareholders and potential investors to remain prudent when trading its securities.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing innovative medicines in Asia. The company targets unmet medical needs in key therapeutic areas, leveraging strategic partnerships and regional expertise to build a differentiated healthcare portfolio for markets including Greater China.
Average Trading Volume: 2,980,616
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.51B
Learn more about 1952 stock on TipRanks’ Stock Analysis page.